Search results: Sage Journals

Open accessResearch articleFirst published 2024

Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC

Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang [...]

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published 2019

Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients

Bin-Chi Liao, Sebastian Griesing, James Chih-Hsin Yang

Therapeutic Advances in Medical Oncology

Restricted accessCase reportFirst published December, 2018

Meeting with triumph and disaster: Osimertinib in T790M-unknown CNS progression in EGFR -mutated non-small cell lung cancer

Francesco Facchinetti, Francesca Bozzetti, Roberta Minari [...]

Tumori Journal

Restricted accessResearch articleFirst published January, 2014

Overcoming T790M-driven Acquired Resistance to EGFR-TKIs in NSCLC with Afatinib: A Case Report

Paola Bordi, Marcello Tiseo, Beatrice Bortesi [...]

Tumori Journal

Open accessReview articleFirst published December, 2016

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

Ivana Sullivan, David Planchard

Therapeutic Advances in Respiratory Disease

Open accessReview articleFirst published June, 2017

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale,evidence and place in therapy

Biagio Ricciuti, Sara Baglivo, Luca Paglialunga [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published January, 2025

Liquid biopsy in clinical outcomes and detection of T790M mutation in metastatic non-small cell lung cancer after progression to EGFR-TKI

David Heredia, Laura Bolaño-Guerra, Angel Valencia-Velarde [...]

Cancer Biomarkers

Open accessReview articleFirst published 2024

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs

Jietao Ma, Letian Huang, Chengbo Han

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2021

Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients

Klaus Hackner, Anna Buder, Maximilian J Hochmair [...]

Clinical Medicine Insights: Oncology

Open accessResearch articleFirst published 2022

Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status

Jun Liao, Yihua Huang, Jiadi Gan [...]

Cancer Control

Open accessResearch articleFirst published 2024

Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC

Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang [...]

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published 2019

Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients

Bin-Chi Liao, Sebastian Griesing, James Chih-Hsin Yang

Therapeutic Advances in Medical Oncology

Restricted accessCase reportFirst published December, 2018

Meeting with triumph and disaster: Osimertinib in T790M-unknown CNS progression in EGFR -mutated non-small cell lung cancer

Francesco Facchinetti, Francesca Bozzetti, Roberta Minari [...]

Tumori Journal

Restricted accessResearch articleFirst published January, 2014

Overcoming T790M-driven Acquired Resistance to EGFR-TKIs in NSCLC with Afatinib: A Case Report

Paola Bordi, Marcello Tiseo, Beatrice Bortesi [...]

Tumori Journal

Open accessReview articleFirst published December, 2016

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

Ivana Sullivan, David Planchard

Therapeutic Advances in Respiratory Disease

Open accessReview articleFirst published June, 2017

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale,evidence and place in therapy

Biagio Ricciuti, Sara Baglivo, Luca Paglialunga [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published January, 2025

Liquid biopsy in clinical outcomes and detection of T790M mutation in metastatic non-small cell lung cancer after progression to EGFR-TKI

David Heredia, Laura Bolaño-Guerra, Angel Valencia-Velarde [...]

Cancer Biomarkers

Open accessReview articleFirst published 2024

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs

Jietao Ma, Letian Huang, Chengbo Han

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2021

Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients

Klaus Hackner, Anna Buder, Maximilian J Hochmair [...]

Clinical Medicine Insights: Oncology

Open accessResearch articleFirst published 2022

Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status

Jun Liao, Yihua Huang, Jiadi Gan [...]

Cancer Control